Pituitary Macroadenoma
A pituitary macroadenoma is a benign tumor of the pituitary gland measuring 1 centimeter or larger. The pituitary is a small gland at the base of the brain that produces hormones which regulate many other endocrine organs. Macroadenomas may cause symptoms through hormone excess (functioning tumors that produce prolactin, growth hormone, ACTH, or, less commonly, TSH or gonadotropins), hormone deficiency from compression of normal pituitary tissue, or local compression of nearby structures—particularly the optic nerves (leading to visual disturbances) and surrounding brain structures. Evaluation combines detailed hormonal testing, dedicated pituitary MRI, and formal visual assessment, with treatment tailored to the specific tumor type.
What is it?
The pituitary gland is a small pea-sized gland located at the base of the brain within a bony recess of the skull called the sella turcica. Despite its small size, the pituitary plays a central role in the endocrine system, producing hormones that regulate many other endocrine glands and body processes. The anterior (front) part of the pituitary produces prolactin (which stimulates breast milk production and affects reproductive function), growth hormone (which regulates growth and metabolism), ACTH (which stimulates the adrenal glands to produce cortisol), TSH (which stimulates the thyroid), and LH and FSH (which regulate reproductive function). The posterior (back) part of the pituitary stores and releases antidiuretic hormone (ADH, or vasopressin, which regulates water balance) and oxytocin.
A pituitary adenoma is a benign tumor arising from the hormone-producing cells of the anterior pituitary. Adenomas are classified by size: microadenomas measure less than 1 centimeter, and macroadenomas measure 1 centimeter or larger. Macroadenomas are more likely than microadenomas to cause symptoms because of their size and their potential to compress nearby structures, and they often lead to endocrine, neurologic, or ophthalmologic findings.
Pituitary macroadenomas are further classified based on whether they produce excess hormones. Functioning (hormone-producing) macroadenomas may secrete prolactin (prolactinomas, the most common functioning tumors), growth hormone (causing acromegaly in adults or gigantism in children), ACTH (causing Cushing disease), or, less commonly, TSH (causing central hyperthyroidism) or gonadotropins (LH and FSH). Nonfunctioning macroadenomas do not produce clinically significant excess hormones and typically present because of symptoms related to compression rather than hormonal effects.
Symptoms of pituitary macroadenomas fall into three main categories.
Hormone excess symptoms depend on the specific hormone produced. Prolactinomas commonly cause menstrual irregularity, absent menstrual periods, milky nipple discharge (galactorrhea), infertility, low libido, erectile dysfunction in men, and, in postmenopausal women or long-standing cases, reduced bone density. Growth hormone excess causes acromegaly in adults, with features such as enlargement of the hands and feet, coarsening of facial features, joint pain, snoring and sleep apnea, high blood pressure, and diabetes; in children before growth plate closure, it causes gigantism. ACTH excess produces the features of Cushing syndrome, including central weight gain, high blood pressure, high blood sugar, easy bruising, thin skin, muscle weakness, mood changes, and osteoporosis. TSH-producing tumors are rare and cause central hyperthyroidism with inappropriately normal or elevated TSH despite elevated thyroid hormones.
Hormone deficiency symptoms result when the macroadenoma compresses and impairs normal pituitary tissue, leading to reduced production of one or more pituitary hormones (hypopituitarism). Features may include fatigue, weakness, cold intolerance, weight changes, low libido, erectile dysfunction, menstrual irregularity, reduced facial or body hair, dry skin, low blood pressure, low blood sugar in severe cases, and, when antidiuretic hormone is affected (uncommon in adenomas but seen after some surgeries), excessive urination and thirst (diabetes insipidus, also called central diabetes insipidus).
Compression of nearby structures, particularly the optic chiasm (where the optic nerves cross above the pituitary), can cause visual disturbances. The classic pattern is bitemporal hemianopia—loss of peripheral vision in both eyes—but other patterns of visual loss can also occur. Compression of the cavernous sinuses (which flank the pituitary and contain cranial nerves and blood vessels) can cause double vision, drooping eyelid, or facial numbness. Headaches are common. Very large tumors can affect the hypothalamus and other brain structures.
Pituitary apoplexy is a rare but potentially serious complication in which sudden bleeding into or infarction of a pituitary tumor causes acute headache, visual loss, and sudden hormone deficiencies. It is a medical emergency.
Most pituitary adenomas occur sporadically. A minority are associated with hereditary syndromes such as multiple endocrine neoplasia type 1 (MEN 1), Carney complex, and familial isolated pituitary adenoma. Prior head and neck radiation is a recognized risk factor. Many patients have no identifiable risk factor.
Diagnosis combines clinical evaluation, comprehensive hormonal testing, imaging, and formal visual assessment. Hormonal testing typically includes prolactin, IGF-1 (a marker of growth hormone activity), morning cortisol and ACTH, TSH and free T4, LH and FSH, estradiol (in premenopausal women) or testosterone (in men), and, when Cushing disease is suspected, 24-hour urinary free cortisol or overnight low-dose dexamethasone suppression testing. Growth hormone stimulation or suppression testing may be needed in specific situations. Prolactin can be falsely elevated by many medications and pregnancy, so interpretation requires clinical context. Very high prolactin levels can sometimes be underestimated by laboratory tests due to a technical issue called the “hook effect,” which should be considered in the setting of a large adenoma with only modestly elevated prolactin.
Dedicated pituitary MRI with and without gadolinium contrast is the primary imaging test. It provides detailed information about tumor size, location, extension into nearby structures (such as the cavernous sinuses or above the pituitary toward the optic chiasm), and imaging features that help characterize the lesion. CT is less commonly used but can show bony detail of the sella and calcifications. Formal visual field testing (perimetry) is performed when the tumor is close to or compressing the optic chiasm.
Certain scenarios warrant additional evaluation. When Cushing disease is suspected but pituitary MRI does not show a clear tumor, or when the source of ACTH excess is uncertain, inferior petrosal sinus sampling (a specialized procedure that measures ACTH from veins draining the pituitary) can help confirm the pituitary source. Genetic evaluation is appropriate when a hereditary syndrome is suspected.
Important to Know
Management of pituitary macroadenomas is highly individualized and depends on the tumor type, size, symptoms, hormonal effects, visual involvement, patient age, comorbidities, and preferences. Care is best coordinated by multidisciplinary teams that include endocrinologists, neurosurgeons with pituitary expertise, neuro-ophthalmologists, radiologists (including neuroradiologists), radiation oncologists, and, when relevant, geneticists.
For prolactinomas, medical therapy is generally the first-line treatment, even for macroadenomas. Dopamine agonists—particularly cabergoline and, less commonly, bromocriptine—are highly effective in most patients at normalizing prolactin levels, restoring normal menstrual and reproductive function, and reducing tumor size. Treatment is usually long-term but may allow gradual dose reduction and, in some patients, discontinuation after several years of good control with a small tumor. Cabergoline is often preferred because of once- or twice-weekly dosing and generally better tolerability. Rare side effects, such as impulse control changes and, at very high doses used in other conditions, heart valve concerns, warrant awareness.
For other functioning macroadenomas (growth hormone–producing, ACTH-producing, TSH-producing) and for symptomatic nonfunctioning macroadenomas—particularly those causing significant compression, visual loss, or hormone deficiencies—transsphenoidal surgery is typically the first-line treatment. This minimally invasive approach reaches the pituitary through the nose and sphenoid sinus, avoiding the need for open cranial surgery in most cases. Surgery is best performed by neurosurgeons with pituitary expertise, ideally in high-volume centers. Success and complication rates depend significantly on tumor characteristics and surgeon experience.
For acromegaly (growth hormone excess), medical therapies such as somatostatin receptor ligands (octreotide, lanreotide, and, in selected patients, pasireotide), growth hormone receptor antagonists (pegvisomant), and dopamine agonists (in some cases) are used before surgery (in specific situations), after incomplete surgical resection, or when surgery is not feasible. For Cushing disease (ACTH excess), medications that reduce cortisol production or block cortisol action are used before surgery, after incomplete resection, or when surgery is not feasible. Rare TSH-producing tumors are typically treated with surgery, often with adjunctive somatostatin analog therapy in selected patients.
Radiation therapy is used in selected patients when surgery has been incomplete, when tumors recur, or when medical and surgical options are limited. Modern techniques include stereotactic radiosurgery (which delivers focused radiation in a single or few sessions) and conventional fractionated radiation therapy. Both approaches carry a risk of new pituitary hormone deficiencies over time, along with less common risks such as vision changes, radiation necrosis, and other complications.
Management of hypopituitarism is essential. Deficiencies of specific pituitary hormones are treated with appropriate hormone replacement, including glucocorticoids for ACTH/cortisol deficiency, levothyroxine for TSH/thyroid deficiency, sex hormones for LH/FSH deficiency (individualized based on age, reproductive plans, and other factors), growth hormone in selected adults and children, and desmopressin for antidiuretic hormone deficiency (central diabetes insipidus). Careful monitoring and dose adjustment are required over time, and patients receive education about stress dosing of glucocorticoids during illness or injury, medical alert identification, and emergency plans.
Follow-up after treatment includes periodic clinical evaluation, hormonal testing, MRI imaging (typically starting a few months after surgery or radiation and continuing at intervals determined by risk of recurrence), and visual assessment as appropriate. Long-term follow-up is important because both functioning and nonfunctioning macroadenomas can recur, and new hormone deficiencies can develop years after treatment.
Pituitary apoplexy is a medical emergency and typically requires prompt hormonal evaluation, emergency glucocorticoid treatment when adrenal insufficiency is suspected, and, in many patients, urgent surgical decompression. Care is delivered in specialized centers with pituitary expertise.
Pregnancy planning and pregnancy require special attention in patients with pituitary macroadenomas. Prolactinomas often require adjustments to dopamine agonist therapy during pregnancy, and tumor size and visual function are monitored, particularly for macroadenomas. Other pituitary conditions and hormone replacements also require careful management during pregnancy.
Genetic counseling and evaluation are appropriate for patients with suspected hereditary syndromes, such as those with young age at diagnosis, multiple pituitary tumors, or family history of related tumors.
Care is best provided by multidisciplinary pituitary teams. Imaging, laboratory, and visual findings are interpreted alongside the patient’s symptoms, examination, family history, and broader clinical context rather than in isolation.
Patient education plays an important role. Understanding the specific tumor type, the rationale for the recommended treatment plan, the importance of medication adherence, the recognition of hormone deficiencies and warning signs of complications, and the need for long-term follow-up all contribute to better outcomes.
Red flag symptoms include sudden severe headache (often the worst of one’s life), sudden loss of vision or double vision, drooping eyelid or facial numbness, severe nausea and vomiting, confusion or altered mental status, severe weakness, low blood pressure or signs of shock, high fever with confusion, severe abdominal pain, or rapid clinical deterioration. These warrant immediate emergency evaluation, as they may indicate pituitary apoplexy, adrenal crisis, or other serious complications.